# Exelixis, Inc. – Consensus ‘buy’ rating and -1.6% Downside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc-consensus-buy-rating-and-1-6-downside-potential/4121184488
- Published: 2025-01-22T13:07:18+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** with ticker code (EXEL) have now 22 market analysts covering 
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between $42.00 and $23.00 calculating
the average target price we see $35.61. Now with the previous closing price of $
36.20 this is indicating there is a potential downside of -1.6%. The 50 day moving
average now sits at $35.10 and the 200 moving average now moves to $27.09. The market
capitalization for the company is 10.40B. Currently the stock stands at: $36.43 
USD

 The potential market cap would be $10,233,296,664 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 23.5, revenue per share of $7.03
and a 12.81% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on:
